The Scripps Research Institute

Vividion Therapeutics, Inc.

Gabe Simon

David S Weinstein

Benjamin F Cravatt

Matthew Patricelli

Benjamin Horning

Ekaterina Vinogradova

Dean Stamos

Todd Kinsella

Brian Nordin

Kristen Baltgalvis

Disclosed herein are compositions and methods for modulating cereblon neosubstrates. A small molecule modulator of Formula (I*), or a pharmaceutically acceptable salt or solvate thereof can be used to modulate cereblon neosubstrates.

Cereblon modulators and uses thereof

Disclosed herein are in vivo engineered cereblon protein and methods of making the same. The in vivo engineered cereblon protein can include a site-specific non-naturally occurring modification at cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3, the modification comprising a moiety resulting from an in vivo Michael addition reaction between an exogenous Michael acceptor and the cysteine 287 as set forth in SEQ ID NO:1, or cysteine 286 as set forth in SEQ ID NO:2 or 3.

In vivo engineered cereblon protein

Growing community of inventors

San Diego, CA, United States of America

Gabe Simon